Central Sooner Research Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$36,261	7
2024	Research	$87,552	150
2023	Research	$69,613	57
2022	Research	$53,325	8
2021	Research	$143,664	4
2020	Research	$74,140	3
2019	Research	$467,641	9

Breakdown

Who paid Research payments · program years 2019–2025

Ironwood Pharmaceuticals, Inc $434,743 8 payments
Eli Lilly and Company $373,993 17 payments
Dermavant Sciences, Inc. $56,387 197 payments
Janssen Research & Development, LLC $55,123 13 payments
Galderma Laboratories, L.P. $11,950 3 payments

Studies the money was for Research payments · program years 2019–2025

C3718-302 $431,883 6 payments
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis $215,491 4 payments
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis Lucent 3 $113,732 7 payments
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $41,623 11 payments
An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $25,995 28 payments
A Phase 3 Multicenter Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis Lucent 3 $24,089 1 payment
An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $23,301 135 payments
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment $13,500 2 payments
A Multicenter Phase 3B Open-Label Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab $11,045 2 payments
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis $6,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.